VENUS®
Enjoy Innovations

VRL/SEC/NSE/92

October 29th, 2012

National Stock Exchange of India Ltd..
5th Floor , Exchange Plaza
Bandra (E), Mumbai- 400 051

Sub. : Venus Remedies bags first Mexican patent for research product – "Vancoplus®"

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has received its first patent from Mexico for "Vancoplus®", a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. The patent has been granted from the Mexico Patent office and is valid till February 2026.

Receiving a patent grant from Mexico for the research product Vancoplus® at this point in time when the frequency of MRSA strains is growing high (50-85%) in Mexico is a great achievement for the Company. Vancoplus® will prove to be the best known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria in a situation wherein around 3 to 6 percent of the population carries the community form of MRSA.

As per the CDC reports published in the Journal of the American Medical Association in 2010, MRSA infections are constantly on the rise in the community and resistance against antibiotics with nearly 48% of S. aureus isolates were resistant to oxacillin (MRSA), and 49% were resistant to levofloxacin; 33% of Enterococcus faecium isolates were resistant to vancomycin and so on.

With the present scenario in mind, this novel product 'Vancoplus' can prove to be a life saving solution in Mexico to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin structure infections and staphylococcal endocarditis.

The value of the pharmaceutical markets in Latin America is at $50 billion, growing at the CAGR of approximately 15- 20%. Mexico being the second leading market in the region represents a growing consumer base for the drug industry as by 2020 the regional population may be as high as 687 million. Venus Remedies is currently exporting to the various countries of LAC such as Columbia, Peru, Guatemala, Dominican Republic, Jamaica, Bahamas and the Caribbean. Its export to LAC has been growing at a rate of near 100% in the past 3 years and LAC is contributing around 15% of the total exports. Receiving a patent grant from Mexico is definitely going to give a boost to the company's export in the region as we have already filed for market authorisation in various countries such as Mexico and few more countries in LAC.

Vancoplus has the potential to restrict transfer of bacterial resistance from MRSA to other strains by preventing conjugation and transfer of plasmids containing resistant genes. "VANCOPLUS®" is also the only known therapeutic option for breaking of bacterial biofilm formed by gram positive bacteria, one of the most common causes of bacterial resistance.

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL
UKAS QUALITY MANAGEMENT
UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 29 Oct. 2012 12:26 P 1

VENUS®
Enjoy Innovations

The total market size of MRSA in the world accounts for $ 9 billion. At present it is growing at CAGR of 4.8 per cent which is estimated to reach to $ 12.4 billion by 2017. Venus expects to grab a fair share of this market within 3 years of launch of its novel research product "VANCOPLUS®" in all major territories of the world.

VANCOPLUS®, a strategically designed formulation through CVMC technology, is the landmark achievement of Venus Medicine Research Center team. The formulation is the most effective and safe option available in the market to curb the notorious Methilicillin Resistant Staphylococcus Aureus (MRSA) strain and multi-drug resistant microbes primarily responsible for causing various infections and Staphylococcal Endocarditis. In addition to its effectiveness in curbing infections, VANCOPLUS® therapy also significantly reduces treatment time and cost and can be considered as empiric therapy to curb menace of MRSA.

The product VANCOPLUS® has already received 7 patent grants from countries such as Australia, USA, Japan, Canada, South Africa, New Zealand and Ukraine. Patents grants for VANCOPLUS® from Europe, Brazil and India are awaited. VANCOPLUS® has already been successfully launched in several markets worldwide and is under registration in many countries.

Yours faithfully,
for VENUS REMEDIES LIMITED.

Ramanjit

Ramanjit Kaur
Assistant Manager
Corporate Communication

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL
UKAS QUALITY MANAGEMENT
UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 29 Oct. 2012 12:27 P 2